Tango TherapeuticsTNGX
Oncology6 cited findings · profile updated 2026-08-20
25.20 USDnot live — refreshed daily
About Tango Therapeutics
Tango Therapeutics (TNGX) is an oncology research site. The company is studying vopimetostat + daraxonrasib in a Phase 1/2 trial for MTAP-deleted, RAS-mutant pancreatic cancer. This combination demonstrated an objective response rate of 92% and a six-month progression-free survival rate of 90% in this patient population.
Further research includes vopimetostat + RAS(ON) inhibitors, with an upcoming presentation at the 2026 ESMO Congress in Madrid, Spain. Initial data for TNG456 is anticipated in 2H 2026.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Objective Response Rate | 92% (vopimetostat + daraxonrasib) | Tango Therapeutics, Inc. — SEC 8-K (2026-08-11), p.1 |
| Six-month Progression-Free Survival Rate | 90% (vopimetostat + daraxonrasib) | Tango Therapeutics, Inc. — SEC 8-K (2026-08-11), p.1 |
| Upcoming Presentation | 2026 ESMO Congress (vopimetostat + RAS(ON) inhibitors) | Tango Therapeutics, Inc. — SEC 8-K (2026-08-11), p.2 |
| Initial Data Release | 2H 2026 (TNG456) | Tango Therapeutics, Inc. — SEC 8-K (2026-08-11), p.2 |
Key projects
- vopimetostat + daraxonrasib (MTAP-deleted, RAS-mutant pancreatic cancer)
This combination is being studied in a Phase 1/2 trial.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →